- Y-mAbs Therapeutics ( NASDAQ: YMAB ) said on Monday its partner Adium Pharma S.A. had submitted a regulatory filing for the approval of Danyelza to treat relapsed/refractory high-risk neuroblastoma to the Brazilian Health Regulatory Agency.
- The company said if the drug us approved. it will work closely with Adium on the production and logistic planning for DANYELZA.
- Researchers at Memorial Sloan Kettering Cancer Center developed DANYELZA, which is exclusively licensed by MSK to Y-mAbs.
For further details see:
Y-mAbs submits application for the approval of Danyelza in Brazil